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Abstract
Individuals who are infected with Trypanosoma cruzi devel-
op chronic Chagas cardiomyopathy (CCC), which is a compli-
cation involving a series of immune pathogenetic mecha-
nisms, although an association between immune and meta-
bolic alterations was more recently proposed. Accordingly, 
we investigated the immuno-metabolic response in chagas-
ic patients and their possible influence on CCC pathogene-
sis. To this end, T. cruzi-seropositive (asymptomatic or with 
CCC) and sero-negative individuals were studied. Serum tu-
mour necrosis factor (TNF)-α, interleukin (IL)-6, adipocyto-
kines and the expression of their receptors in peripheral 
blood mononuclear cell (PBMC) were evaluated, together 
with other factors influencing the immune response. CCC 
patients showed major metabolic and hormonal abnormali-
ties, in parallel with increased IL-6 and leptin serum levels. 
TNF-α receptor s, leptin and adiponectin receptors (ObR and 
Adipo-Rs respectively), as well as PPAR-γ expression in 
PBMCs from CCC patients were compatible with a counter-
acting response leading to an unfavourable immune-meta-
bolic profile. These results suggest that persistently in-
creased levels of immune-metabolic pro-inflammatory me-
diators along with the adverse endocrine anti-inflammatory 
response of CCC individuals, may contribute to the underly-
ing mechanisms dealing with myocardial tissue damage.
© 2018 S. Karger AG, Basel
Introduction
Chagas disease, caused by the parasite Trypanosoma 
cruzi, is considered a major health problem in Latina 
America. However, in the last decade, migratory flows 
have spread this disease into the United States, Europe 
and Asia [1]. These studies estimated that the disease bur-
den, measured by disability-adjusted life-years, is 7.5 





















   
   
   
   
   
   
   
   
   
   
























caused by vectorial, congenital or oral transmission, al-
though transfusional or transplant transmission was also 
reported [3]. During vectorial or congenital transmission, 
the acute phase is usually asymptomatic, lasting ∼2–3 
months. After that, patients evolve to a chronic infection, 
where many of them remain asymptomatic for their life-
time. However, ∼30% of the chronically infected indi-
viduals progress to evident disease, with the development 
of different degrees of cardiac or digestive disturbances 
[4]. It is estimated that chronic Chagas cardiomyopathy 
(CCC) causes ∼50,000 deaths per year [5].
During many years, chronic Chagas disease was main-
ly regarded as an autoimmune pathology. In the 1990s, 
the finding of T. cruzi DNA in myocardial inflammatory 
lesions by PCR, gave more support to the theory of para-
site persistence as one of the causes of tissue and func-
tional damage during the chronic stage. CCC is mainly 
characterized by focal inflammatory lesions with de-
struction of cardiomyocytes and driving nerve fibres, 
collectively involved in the development of cardiomega-
ly, heart block, arrhythmias, congestive heart failure or 
stroke [4].
Immune mechanisms linked to the development of 
CCC are highly heterogeneous and not yet fully under-
stood, raising the need to investigate whether additional 
components, like metabolic and endocrine factors, are 
also involved in disease morbidity. It is known that the 
metabolic status is finely tuning by nutrition, energy ex-
penditure and hormonal signals. The communication 
between general metabolism and the immune response 
also comprises a series of pleiotropic products able to 
modulate appetite, endocrine functions, energy expen-
diture and inflammation, lastly affecting the regulation 
of energy sources and immune activity. Pro-inflamma-
tory cytokines like tumour necrosis factor (TNF)-α and 
interleukin (IL)-6 and adipose tissue derived compo-
nents like adipocytokines are also involved in the regula-
tion of food intake [6, 7]. Moreover, hormones like glu-
cocorticoids and dehydroepiandrosterone (DHEA), 
which may influence both metabolic and inflammatory 
responses [8–11], should also be considered in this com-
plex scenario.
In this regard, a previous study carried out in a small 
group of urbanized patients with chronic Chagas’ disease, 
showed that the more severe forms of myocarditis coex-
isted with immune-endocrine imbalances and a trend to 
overweight [12]. Coincidentally, another study detected a 
higher prevalence of diabetes in chagasic women with 
chronic myocarditis than in the general population [13]. 
Moreover, a recent work in chronically T. cruzi-infected 
mice showed that an obesogenic context promotes the 
development of cardiovascular disorders [14].
In this context, recent studies revealed that inflamma-
tory chronic diseases present complex metabolic facets, 
with alterations in the relationship between catabolic and 
anabolic factors affecting diverse tissues and organs. 
Whether the fat tissue plays a role in human Chagas dis-
ease progression or in the severity of CCC has not been 
properly elucidated. There is evidence on the possible 
contribution of adipose tissue to T. cruzi-induced pathol-
ogy in mice, but many of them are focused in the acute 
phase of infection [15–19]. Nevertheless, when consider-
ing that the adipose tissue seems to be one of the main 
reservoirs of T. cruzi during the chronic phase of disease 
[20], the possibility that a disbalance between certain fat 
inflamed-derived metabolic factors (like TNF-α, IL-6, 
leptin and adiponectin) as contributing to cardiomyopa-
thy progression and severity, sounds likely. For instance, 
unbalanced adipocytokines were associated with the 
presence of sympathetic dysfunctions in patients with 
CCC [21]. Moreover, cortisol/DHEA ratios, rather than 
the individual concentrations seem to be more represen-
tative of disease activity [11, 12].
It follows that disturbances in metabolic circuits might 
contribute to the pathogenesis and aggravation of human 
CCC. Here, we investigated the metabolic status in pa-
tients with chronic Chagas disease and examined wheth-
er there is a relation between metabolic, immune and en-
docrine patterns with the severity of MCC.
Materials and Methods
Patients
The study population consisted of 242 individuals, separated into 
190 T. cruzi chronically infected patients and 52 age-matched healthy 
volunteers (control) of both sexes, recruited at the Chagas Section of 
the Cardiology Service of Hospital Provincial del Centenario de Ro-
sario, Argentina. None of these patients was under specific treatment 
(i.e., benznidazole or nifurtimox) nor had concomitant pathological 
disorders. Exclusion criteria comprised other cardiac disease, neu-
roendocrine disturbances, major metabolic diseases (as diabetes), 
immunological diseases, or treatment with hormones or immuno-
modulators. Control subjects were seronegative to T. cruzi-specific 
tests. The diagnosis of Chagas disease was based on at least 2 positive 
serological findings according recommendations of the WHO, to-
gether with clinical symptoms, chest X-ray and 12-lead resting elec-
trocardiogram (ECG). Chronic chagasic patients were grouped as 
follows: Asymptomatic (Asy; n = 84), with normal ECG and chest 
X-ray. CCC patients were subclassified into 2 groups: (a) Mild-to-
Moderate cardiac patients (M, n = 55), with no congestive heart fail-
ure and ECG showing any of the following alterations: incomplete 





















   
   
   
   
   
   
   
   
   
   
























atrioventricular block or non-life-threatening arrhythmias or a chest 
X-ray cardiothoracic ratio < 0.55; (b) Severe patients (SEV, n = 51), 
presenting major ECG pathological tracings, that is, complex ven-
tricular arrhythmia or complete atrioventricular block; congestive 
heart failure and a chest X-ray cardiothoracic ratio > 0.55. As part of 
the physical examination, different anthropometric measurements 
were recorded. The population recruitment approach fit well with a 
consecutive non-probabilistic sample, rendering a predominant 
number of females in all study groups. 
Simple ECG Score
The systematic ECG recording in endemic areas has allowed 
the possibility to describe several aspects of the natural electrocar-
diographic history of CCC, like the time of appearance and types 
of alterations noticed [22]. Based on this description, we developed 
a simple ECG score according to the progressive degree of altera-
tions ranging from early to late electrocardiographic findings: 
RBBB (score 1); left anterior hemiblock (score 2); left bundle 
branch block (score 3); supraventricular extrasystoles (score 4); 
ventricular extrasystoles (score 5); first degree of atrioventricular 
block (score 6); supraventricular tachycardia (score 7); non-sus-
tained ventricular tachycardia (score 8); complex ventricular 
tachycardia (score 9); and complete atrioventricular block (score 
10). We calculated a simple scoring consisting of the summation 
of these point scores. Afterwards, we tested the eventual associa-
tion between individual ECG scores and metabolic parameters. 
Plasma Collection for Cytokine, Adipocytokines and HPA 
Axis-Linked Hormone Assays
Fasting blood samples from patients and control were collected 
between 8: 00 and 10: 00 a.m. Plasma was obtained from EDTA 
treated blood. Samples were centrifuged at 2,000 rpm during 30 
min and then preserved at –70  ° C. Plasma cytokine concentrations 
were assessed using commercially available enzyme-linked immu-
nosorbent assay kits: IL-6 (R&D), TNF-α (BD OptEIA), adiponec-
tin (Invitrogen) and leptin (Peprotech), following manufacturer’s 
indications. Plasma cortisol and DHEA sulphate (DHEA-S) were 
measured in duplicate by electrochemiluminescence immunoas-
say (Roche Diagnostics). 
Metabolic Variables
The HOmeostasis Model Assessment of Insulin Resistance 
(HOMA-IR) index was calculated as (glucose [mg/dL] × insulin 
[µUI/mL])/405. Fasting glycaemia was evaluated by the glucose-
oxidase assay (Wiener Lab.), whereas fasting insulin levels were 
assayed by the electrochemiluminescence method (Roche Diag-
nostics). Body mass index (BMI) was calculated as weight/height2 
(kg/m2). Glycosylated haemoglobin and the lipid profile were de-
termined by routine laboratory methods.
Metabolic Syndrome was defined using the International Dia-
betes Federation criteria [23, 24]. They take into account central 
obesity as a prerequisite risk factor for metabolic syndrome, which 
can be easily assessed using waist circumference (male: ≥94 cm; 
female: ≥80 cm) or BMI ≥30 kg/m2, plus 2 of the following factors: 
raised fasting plasma glucose (> 100 mg/dL), high level of triglyc-
erides (> 150 mg/dL); reduced high density lipoprotein (HDL) 
cholesterol (< 40 mg/dL in males and < 50 mg/dL in females) and 
increased blood pressure (systolic blood pressure > 130 or diastol-
ic blood pressure > 85 mm Hg), or specific treatments for any of 
these alterations.
Mononuclear Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were obtained 
from fresh EDTA-treated blood. The cell suspension was layered 
over a Ficoll-Paque-PLUS (GE-Healthcare) gradient and centri-
fuged at 400 g for 30 min at 25  ° C. The buffy coat was washed and 
re-suspended in RPMI 1640 (Gibco) and 8 × 106 cells and re-sus-
pended in TRI-Reagent® (MRC) for RNA isolation and stored at 
–80  ° C until used.
RNA Isolation, cDNA Synthesis and qPCR
Total RNA was isolated using TRI-Reagent® according to the 
manufacture’s recommendations. The level of mRNA expression 
was determined by RT-qPCR. cDNA was synthesized from 2 ng of 
total RNA using M-MLV reverse transcriptase (Invitrogen) and 
specific primers for TNF-α receptor type-1 (TNF-R1), TNF-R2, 
ObR, Adipo-R1, Adipo-R2 and PPAR-γ. PCR reactions were per-
formed in a Stratagene MX3000P real-time PCR System (Strata-
gene), using the HOT FIREPol EvaGreen qPCRMix Plus with 
ROX master mix (SolisBiodyne), according to the manufacturer’s 
recommendations. Data was normalized using cyclophilin A 
cDNA quantification. 
Primer sequences used in this study were:
Cyclophilin A: F 5′-GGTCCTGGCATCTTGTCCAT-3′; R 
5′-TTGCTGGTCTTGCCATTCCT-3′.
Adipo-R1: F 5′-CATCTACCTCTCCATCGTCTGTG-3′; R 
5′-CATGAGGAAGAACCAGCCCATC-3′.
Adipo-R2: F 5′-CAGATAGGCTGGTTGATGCTGA-3′; R 
5′-GCCGATCATGAAACGAAACTCC-3′.
ObR (Include all ObR isoforms): F 5′-GCCAGTCTTTC-
CAGAGAATAACCT-3′; R 5′-CAACTGTGTAGGCTGGATT-
GCT-3′.
PPAR-γ (Include PPAR-γ1 y PPAR-γ2 isoforms): F 
5′-TTTCAGAAATGCCTTGCAGTGG-3′; R 5′-CTTTCCTGT-
CAAGATCGCCCTC-3′.
IL-6R: F 5′-ATGTTGTTTGTGAGTGG-3′; R 5′-GACGCA-
CATGGACACTATGTAGA-3′.
TNF-R1: F 5′-AGAGCCTAGACACTGATGACC-3′; R 5′-AG-
CATGCTGTATTGCGCCT-3′.
TNF-R2: F 5′ -ACTTCGCTCTTCCAGTTGGACT-3′; R 5′-AG
GGCTTCTTTTTCACCTGGG-3′.
Statistical Analysis
Parametric (analysis of variance followed by Tukey or Student 
t test) or non-parametric tests (Kruskall-Wallis followed by Bon-
ferroni test or the U the Mann-Whitney) were used depending on 
the specific variable characteristics. Pearson correlation analysis 
was also used. Categorical variables were analysed by the χ2. Given 
that many factors evaluated in this study showed a sexual dimor-
phism and age-related variations, both potential confounders were 
controlled by the unconditional logistic regression method. The 
level of significance was set at p < 0.05.
Ethics Statement
The study was conducted according to the Helsinki Declaration 
and the protocol was approved by the Institutional Ethics Com-
mittee of the Medical Faculty of National University of Rosario. 
Participants were enrolled and gave their informed consent before 






















   
   
   
   
   
   
   
   
   
   


























The characteristics of chronic Chagas disease patients 
and healthy controls are shown in Table 1. All individuals 
were recruited at the Chagas Section of the Cardiology 
Service of Hospital Provincial del Centenario, Rosario, 
Argentina. Although the mean age was slightly higher in 
CCC patients than in the Asy ones (mostly due to the 
natural disease progression), age ranges did not differ 
among groups. There were more women than men in the 
total sample, but their frequency in each group was simi-
lar (χ2 test). Among M patients, RBBB and LAH were the 
most prevalent ECG findings, while in SEV cases, 56% of 
them showed atrioventricular block (online suppl. Table 
1; for all online suppl. material, see www.karger.com/
doi/10.1159/000491699). 
Metabolic Parameters in Individuals with Chronic 
Chagas Disease
In the study population, individuals with chronic 
Chagas disease had a higher BMI than healthy individu-
als (Fig. 1a). In fact, 42% of total chagasic individuals 
presented BMI values compatible with obesity. This dif-
ference remained significant when chagasic individuals 
were sub-classified based on the presence or absence of 
myocardiopathy (Fig. 1b), with no differences between 
Asy and SEV cases (data not shown). A similar trend 
was observed in the waist/hip ratio (control = 0.84 ± 0.0, 
Asy = 0.88 ± 0.1*, CCC = 0.90 ± 0.1*; p < 0.05 vs. con-
trol). We also observed differences in glycemia between 
control and chagasic individuals (Fig. 1c, d), more no-
ticeable in SEV patients that showed the highest blood 
glucose values (control = 84.2 ± 1.5; Asy = 88.7 ± 1.7, 
M = 88.8 ± 2.4, SEV = 90.1 ± 2.5, *p < 0.05 vs. control). 





CCC (n = 106) p value
M (n = 55) SEV (n = 51)
Age, years 47.2±1.9 45.3±1.4 52.2±1.7* 52±1.7* <0.05* vs. Asy
Range, min–max 18–73 18–76 21–76 18–79
Gender, M:F 20:32 28:56 9:46 17:34 –ns (χ2)
Systolic blood pressure, mm Hg 120±1.7 120±2.0 130±2.7 130±1.8
Diastolic blood pressure, mm Hg 70±1.8 74±1.3 77±1.4 80±1.2
Co, control; Asy, asymptomatic; CCC, chronic Chagas cardiomyopathy; M, mild to moderate CCC; SEV, se-
vere CCC, M:F, masculine/feminine number of individuals; min–max, minimum value-maximum value. Age 


































































































Fig. 1. Metabolic parameters in patients with Chagas disease in re-
lation to healthy individuals. All parameters were evaluated de-
pending on the presence (chronic Chagas cardiomyopathy [CCC]) 
or absence of cardiac pathology (Asy). a, b Body mass index (BMI), 
calculated as ([kg]/height2 [m]); c, d glycemia; e, f insulin; g, h 
HOmeostasis Model Assessment of Insulin Resistance (HOMA-






















   
   
   
   
   
   
   
   
   
   
























Logistic adjustments indicated that glycaemia was not 
influenced by the BMI, or age, irrespective of the group. 
Although in our studies diabetic individuals were ex-
cluded, values of glycosylated haemoglobin in SEV pa-
tients were above the upper normal limit and statisti-
cally different from control values (control = 5.5 ± 0.1; 
Asy = 5.6 ± 0.1; M = 5.6 ± 0.1: SEV = 6.1 ± 0.1*p < 0.05 
vs. control). This difference remained significant upon 
BMI adjustment. Unlike glycaemia, insulin levels were 
clearly increased in chagasic patients (Fig. 1e), either in 
Asy or CCC patients (Fig. 1f, p < 0.05 respect to control), 
without differences between M and SEV. Differences in 
insulin levels disappeared upon adjusting for the BMI. 
The same was true when analysing HOMA-IR, whose 
values in Asy and CCC patients appeared above those 
from control (Fig.  1g, h). Again, such differences be-
came insignificant after adjusting for the BMI. Reported 
differences were also unmodified by age- or sex-adjust-
ments. It follows that insulin and HOMA-IR alterations 
of chagasic individuals may be linked to the increased 
BMI. It also seems clear that regulation of glycemia re-
quires a greater insulin secretion, resembling to some 
extent a pre-diabetic situation. Also, ∼30% of chagasic 
individuals presented metabolic syndrome as defined 
by the International Diabetes Federation criteria. Cor-
relation analyses within the whole sample of CCC pa-
tients showed no relation between ECG score and the 
BMI. Nevertheless, when SEV patients were excluded, 
the BMI rise of M patients was associated with the pro-
gression of pathological ECG findings (Table 2), sug-
gesting that a low but active systemic inflammation may 
favour the initial myocardial lesions that compromise 
the cardiac conduction system. Lipid profile analyses 
showed that although values oscillated within the nor-
mal range, ∼30% of chagasic patients showed increased 
amounts of triglycerides (≥150 mg/dL) or lower levels 
of HDL (≤40 mg/dL) compared to control individuals, 
regardless of the degree of cardiac involvement (online 
suppl. Table 2).
The bulk of these results suggested that in chagasic pa-
tients the immune response may be influenced by meta-
bolic alterations.
Immune-Metabolic Markers in Individuals with 
Chronic Chagas Disease
Next, we evaluated two key cytokines involved both in 
infection control and myocardial damage: IL-6 and 
TNF-α. As expected, levels of circulating IL-6 were high-
er in chronic chagasic patients than in control (Fig. 2a), 
this difference being due at the expense of the CCC group 
(Fig.  2b), regardless of age or BMI. Changes in TNF-α 
moved in the same direction (Fig. 2c, d), although the in-
creased levels displayed by CCC patients did not reach the 
levels of statistical significance. Adjustments for BMI, sex 
or age could not be applied because the variable deviated 
from the normal distribution. DHEA-S values in chagas-
ic individuals situated below the control counterparts 
(Fig. 2e), being even lower in the CCC group (Fig. 2f). The 
same overall difference was seen when DHEA-S levels 
were age-adjusted. Further separation of patients by sex 
followed by age adjustment revealed that decreased 
DHEA-S levels remained statistically significant only in 
SEV women (p < 0.05). Chagasic individuals also showed 
a slight but significant hypocortisolemia in relation to 
control, irrespective of the clinical form (Fig. 2g, h), sug-
gestive of a relative adrenal insufficiency. The cortisol/
DHEA-S ratio appeared increased in chagasic patients 
(Fig. 2i), but differences were only significant when com-
paring CCC patients with control and Asy cases (p < 0.05 
and p < 0.005, respectively; Fig. 2j). The approach of sep-
arating by sex and adjusting according to age rendered 
differences insignificant. Compared to control, leptin lev-
els were significantly higher in individuals with chronic 
Chagas disease (Fig. 2k), mostly driven by the CCC group 
(Fig. 2l). Upon adjustment for BMI, such differences re-
mained significant in women (p < 0.05), but were no lon-
ger observed in male patients. The trend of chagasic pa-
tients to show decreased adiponectin levels (Fig. 2m), at-
Table 2. ECG score according to the body mass index categories of chronic chagasic patients with cardiomyopa-
thy
ECG score BMI <25 BMI 25–30 BMI 30–35 BMI >35
M 3 (2–3.25) 3 (2.75–5) 4 (2–6) 5 (1.5–6.75)
SEV 11 (9–14) 10 (10–11) 10 (8.5–13.5) 11 (7.75–15.25)
ECG, electrocardiogram; BMI, body mass index; M, Mild to Moderate cardiomyopathy; SEV, Severe cardio-





















   
   
   
   
   
   
   
   
   
   
























tained statistical significance in the case of Asy cases (p < 
0.05 vs. control; Fig. 2n), with differences following BMI 
adjustment remaining significant only among women 
(p < 0.05). 
Expression of Immune and Immuno-Metabolic 
Related Receptors in Peripheral Mononuclear Cells 
from Patients with Chronic Chagas Disease
To get some insight into the ability of immunocompe-
tent cells to respond to circulating cytokines and adipocy-
tokines, we further evaluated the expression of Adipo-R1, 
Adipo-R2, leptin receptor (ObR, all isoforms), IL-6R, 
TNF-R1 and TNF-R2 in PBMC. These assays were per-
formed in fewer individuals because of operational issues. 
We also evaluated the expression of PPAR-γ, since its ac-
tivation has modulatory effects on the immune and meta-
bolic response of immune cells by inhibiting the release of 
inflammatory mediators, that is, TNF-α and leptin [25, 
26], in addition to inhibiting the activation of T lympho-
cytes [27]. The present analysis indicated that PPAR-γ 
transcripts tend to be increased in CCC individuals, with-
out reaching the level of statistical significance (Fig. 3a). 
Interestingly, a significant increase in the expression of 
Adipo-R1 and Adipo-R2 was seen in CCC patients (Fig. 3b, 
c), whereas ObR transcripts were found sharply decreased 
in the same group (Fig. 3d). The assessment of IL-6R ex-
pression revealed no between-group differences (Fig. 3e). 
PBMC from chagasic patients had an increased expression 
of TNF-R1 and TNF-R2 respect to control, statistically sig-
nificant in the case of TNF-R2 (Fig. 3f, g). The bulk of data 
suggests that immunocompetent cells tend to counterbal-
ance the reported immuno-metabolic alterations.
Discussion
Currently, there is vast evidence pointing out that ex-
cessive weight gain, inflammation and the endocrine and 
metabolic disorders are closely related with the immune 
phenomena impacting at the cardiac level. Until a few 
years ago, the impact that this set of variables could have 
had on the severity of CCC was poorly appreciated. Nev-
ertheless, some evidence from laboratory animals and hu-
man studies suggests that metabolic alterations triggered 
by the western lifestyle can influence the progression of 
Chagas disease [14, 19]. 
Within this setting, we have proceeded to evaluate a 
substantial number of urbanized and chronically-infect-
ed chagasic patients, to show that a considerable amount 












































































































































































Fig. 2. Plasma levels of immuno-metabolic mediators in healthy 
and chagasic patients subdivided according to myocardial involve-
ment. Cytokines: interleukin (IL)-6 (a, b); tumor necrosis factor 
(TNF)-α (c, d); hormones: DHEA-S (e, f); cortisol (g, h); cortisol/
DHEA-s (i, j); adipocytokines (k–n). The results are expressed as 





















   
   
   
   
   
   
   
   
   
   
























obesity. Similarly, it has been reported that chagasic indi-
viduals residing in non-endemic areas of Brazil also man-
ifested overweight [28], likely due to changes in their eat-
ing habits when migrating from endemic areas to large 
cities [29]. Within this setting, present patient series had 
increased insulin, triglycerides, HOMA-IR index in pres-
ence of lower levels of HDL likely compatible with a pre-
diabetic situation, which in turn may increase the risk for 
cardiovascular disorders. 
Overweight and obesity have a strong impact on the 
immune response, both being considered chronic low-
grade inflammation states [30, 31]. In these conditions, 
adipocyte hypertrophy not only leads to the recruitment 
of inflammatory cells but also decreases Treg cells [32–
35], in addition to promoting IL-6 and TNF-α secretion 
by macrophages and adipocytes [35, 36]. The decreased 
presence of HDL may also favour the chronic inflamma-
tory state given the anti-inflammatory properties of this 
lipoprotein. Since some of these abnormalities are pres-
ent in CCC patients, such alterations are likely to underlie 
the pathogenesis of cardiomyopathy. Interestingly, we 
observed an association between the BMI and the ECG 
score – mirroring the degree of cardiac damage – in M 
patients but not in SEV. Perhaps differences in the natural 
evolution of myocardial damage may be due to the initial 
focal inflammatory process, with the severe and well-es-
tablished ECG alterations being more linked to irrevers-
ible cardiac damage because of the protracted fibrosis 
[22]. Accordingly, our results may implicate that an en-
hanced inflammatory background resulting from over-
weight is likely to favour the early development and es-
tablishment of cardiac lesions in chagasic patients. 
Moving to adrenal steroid results, the increased corti-
sol/DHEA-S ratio seen in patients with CCC is reminis-
cent of the abnormal cortisol/DHEA-S relationship re-
ported in non-chagasic heart failure [37] probably be-
cause of the stress resultant from this condition. Although 
BMI adjustment rendered the cortisol/DHEA-S insignif-
icant, the fall in DHEA-S together with the slightly re-
duced cortisol levels of CCC patients points out to a par-
tial deficiency of them to cope with the protracted inflam-
matory response and the subsequent myocardial 
affectation. Studies in the context of acute T. cruzi exper-
imental infection demonstrated that administration of 
DHEA exerted a clear protective effect [38], whereas glu-
cocorticoid blockade increased mortality [39].
As regards to cardiovascular disorders, obesity de-
creases adiponectin secretion and increases leptin resis-
tance [40, 41], which are known to favour the occurrence 
of ventricular hypertrophy, heart failure, atrial fibrilla-
tion, the activation of pro-fibrotic pathways and the ensu-
ing heart fibrosis [42]. Reinforcing this view, adiponectin 
deficient mice display a cardiomyopathic phenotype, 
with insulin resistance and obesity increasing the mortal-
ity associated to acute T. cruzi infection [41, 43]. 
In general terms, our series of chagasic patients had a 
slight hyperleptinemia without major changes in adipo-

























































































Fig. 3. Expression of immuno-metabolic-related receptors in pe-
ripheral mononuclear cells from patients with chronic Chagas dis-
ease: a PPAR-γ. b Adiponectin receptor type-1 (Adipo-R1). c Ad-
iponectin receptor type-2 (Adipo-R2). d Leptin receptor (ObR). 
e  IL-6 receptor (IL-6R). f TNF-α receptor type-1 (TNF-R1). 
g TNF-α receptor type-2 (TNF-R2). The results are expressed as 
arbitrary units and shown as mean ± SEM (n = 15/group, selected 





















   
   
   
   
   
   
   
   
   
   
























[21] reported decreased leptin levels in chagasic patients 
with congestive heart failure, whereas another study [44] 
showed no differences between CCC patients and con-
trols. In both studies, however, the classification of myo-
cardial involvement was different from the present one 
[21, 44]. In line with our findings, leptin levels were found 
increased in non-chagasic individuals with chronic heart 
failure as a reflection of the proposed hypertrophic effects 
of leptin on cardiomyocytes [45, 46]. Since heart enlarge-
ment is a common feature of CCC, a detrimental role of 
increased leptin levels in this regard cannot be ruled out 
[47]. As a non-mutually exclusive possibility, augmented 
leptin levels may be a reflection of increased inflamma-
tion, particularly in SEV patients, acting to account for 
the hormonal alterations of CCC patients because of its 
inhibiting effects on the production of adrenal androgens 
and cortisol [48]. 
The unchanged adiponectin levels seen in our patients, 
contrast with data reporting an autonomic dysfunction-
related hyperadiponectinemia in a dissimilar subgroup of 
patients with advanced heart failure [21]. Although our 
CCC patients failed to show such an increase, they did 
exhibit an enhanced expression of adiponectin receptors, 
suggesting the presence of compensatory mechanisms to 
dampen inflammation. In the same sense, patients with 
chronic non-infectious inflammatory diseases display an 
increased expression of Adipo-Rs in their PBMCs [49, 
50]. The same seems to apply for the expression of other 
receptors involved in anti-inflammatory functions. While 
the inflammatory effect of TNF-α is primarily mediated 
by TNF-R1, in systemic inflammatory diseases, TNF-R2 
was shown to mediate anti-inflammatory functions by 
promoting suppressor T-cell populations [51, 52]. 
PPAR-γ expression, which in our CCC patients displayed 
a tendency to be elevated, was found enhanced in immu-
nocompetent cells from septic patients [53, 54]. Interest-
ingly, PPAR-γ agonist administration to T. cruzi-infected 
mice diminished heart inflammation and fibrosis [55], 
indicating that the anti-inflammatory pathways triggered 
by PPAR-γ activation may ameliorate myocardial dam-
age. Concerning ObR, its decreased expression in PBMCs 
of CCC patients may be mirroring the establishment of 
down-regulatory mechanisms, in terms of inflammation-
mediated tissue damage, as seen in chronic viral hepatitis 
[56]. Although cells infiltrating the myocardium may 
present another pattern of receptor expression due to in 
situ generated signals, the prolonged increase in immune 
and metabolic pro-inflammatory mediators along with 
the scarce endocrine control of inflammation likely to oc-
cur in CCC, emerge as contributing factors for the mech-
anisms underlying myocardial damage (summarized in 
Fig. 4).
In translating to the clinical field, present data sug-
gests that overweight/obesity and its immuno-metabolic 
consequences must be addressed when evaluating indi-
viduals with Chagas disease, particularly when consider-








































Fig. 4. Immune-metabolic imbalances that 
may favour the establishment of chronic 
chagasic cardiomyopathy. The graph sum-
marizes the complex and intricate network 
of immuno-endocrine and metabolic path-
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